An autopsy case of primary gliosarcoma with multiple extracranial metastases: pathology after administration of bevacizumab and genetic profile.

IF 0.9 4区 医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL
Yoshiki Sato, Shoichi Deguchi, Tomoko Norose, Takuma Oishi, Koichi Mitsuya, Takashi Sugino, Yasuto Akiyama, Takeshi Nagashima, Kenichi Urakami, Yuji Shimoda, Keiichi Ohshima, Nakamasa Hayashi, Ken Yamaguchi
{"title":"An autopsy case of primary gliosarcoma with multiple extracranial metastases: pathology after administration of bevacizumab and genetic profile.","authors":"Yoshiki Sato, Shoichi Deguchi, Tomoko Norose, Takuma Oishi, Koichi Mitsuya, Takashi Sugino, Yasuto Akiyama, Takeshi Nagashima, Kenichi Urakami, Yuji Shimoda, Keiichi Ohshima, Nakamasa Hayashi, Ken Yamaguchi","doi":"10.18999/nagjms.85.4.828","DOIUrl":null,"url":null,"abstract":"<p><p>Gliosarcoma (GS), a morphological variant of glioblastoma, pathologically shows a biphasic pattern with gliomatous and sarcomatous components. It has been reported that GS has much higher metastatic capacity than glioblastoma. A few reports on the pathology of the extracranial metastasis of GS have shown that metastatic lesions had a sarcomatous component alone or a mixture of gliomatous and sarcomatous ones. Therefore, it is considered that GS tends to disseminate hematogenously due to its mesenchymal sarcomatous component. Herein, we report an autopsy case of GS with multiple extracranial metastases treated by craniotomy, radiotherapy, and bevacizumab. In this case, metastatic lesions at autopsy contained a gliomatous component alone, but no sarcomatous component. In addition, the sarcomatous component disappeared from the intracranial lesion at autopsy after the administration of bevacizumab. In this report, we discuss the clinical course and pathological findings at the initial state, recurrence, and autopsy, including the results of whole-genome analysis.</p>","PeriodicalId":49014,"journal":{"name":"Nagoya Journal of Medical Science","volume":"85 4","pages":"828-835"},"PeriodicalIF":0.9000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10751501/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nagoya Journal of Medical Science","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.18999/nagjms.85.4.828","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Gliosarcoma (GS), a morphological variant of glioblastoma, pathologically shows a biphasic pattern with gliomatous and sarcomatous components. It has been reported that GS has much higher metastatic capacity than glioblastoma. A few reports on the pathology of the extracranial metastasis of GS have shown that metastatic lesions had a sarcomatous component alone or a mixture of gliomatous and sarcomatous ones. Therefore, it is considered that GS tends to disseminate hematogenously due to its mesenchymal sarcomatous component. Herein, we report an autopsy case of GS with multiple extracranial metastases treated by craniotomy, radiotherapy, and bevacizumab. In this case, metastatic lesions at autopsy contained a gliomatous component alone, but no sarcomatous component. In addition, the sarcomatous component disappeared from the intracranial lesion at autopsy after the administration of bevacizumab. In this report, we discuss the clinical course and pathological findings at the initial state, recurrence, and autopsy, including the results of whole-genome analysis.

一例原发性胶质肉瘤伴多发性颅外转移的尸检病例:贝伐珠单抗用药后的病理和基因图谱。
胶质肉瘤(GS)是胶质母细胞瘤的一种形态变异,病理上表现为胶质瘤和肉瘤的双相模式。据报道,胶质肉瘤的转移能力远高于胶质母细胞瘤。一些关于葛细胞瘤颅外转移病理的报告显示,转移病灶中只有肉瘤成分,或胶质瘤和肉瘤成分混合。因此,有学者认为,GS因其间充质肉瘤成分而倾向于血行播散。在此,我们报告了一例通过开颅手术、放疗和贝伐珠单抗治疗的伴有多发颅外转移的戈谢病尸检病例。在该病例中,尸检发现的转移灶仅含有胶质瘤成分,而无肉瘤成分。此外,在使用贝伐珠单抗后,尸检时颅内病变中的肉瘤成分也消失了。在本报告中,我们讨论了患者的临床病程、初始状态、复发和尸检时的病理结果,包括全基因组分析的结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Nagoya Journal of Medical Science
Nagoya Journal of Medical Science MEDICINE, RESEARCH & EXPERIMENTAL-
CiteScore
1.30
自引率
0.00%
发文量
65
审稿时长
>12 weeks
期刊介绍: The Journal publishes original papers in the areas of medical science and its related fields. Reviews, symposium reports, short communications, notes, case reports, hypothesis papers, medical image at a glance, video and announcements are also accepted. Manuscripts should be in English. It is recommended that an English check of the manuscript by a competent and knowledgeable native speaker be completed before submission.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信